Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A very rare, severe, interstitial lung disease of insidious onset with subacute or chronic non-specific respiratory manifestations (dyspnea, cough, wheezing) often associated with systemic manifestations (fatigue, malaise, weight loss).
Biomarker and diagnostic research for idiopathic chronic eosinophilic pneumonia has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for idiopathic chronic eosinophilic pneumonia.
36 publications have been identified in PubMed for idiopathic chronic eosinophilic pneumonia. Research spans Case Report / Case Series (47%), Review / Meta-Analysis (22%), and Other (11%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 17 | 47% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 6:47 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Research summaries
8 |
22% |
Other research | 4 | 11% |
Disease patterns and progression | 4 | 11% |
Testing and diagnosis research | 2 | 6% |
Clinical study results | 1 | 3% |
Gupta N (2026). [PMID: 41553241](https://pubmed.ncbi.nlm.nih.gov/41553241/). *Clin Nucl Med*. [Diagnostic / Biomarker]
Ishikawa M (2026). [PMID: 41346175](https://pubmed.ncbi.nlm.nih.gov/41346175/). *Int Forum Allergy Rhinol*. [Other]
Bouali S (2026). [PMID: 41841088](https://pubmed.ncbi.nlm.nih.gov/41841088/). *Cureus*. [Case Report / Case Series]
Pahal P (2026). [PMID: 30725854](https://pubmed.ncbi.nlm.nih.gov/30725854/). *Unknown Journal*. [Review / Meta-Analysis]
Emmi G (2026). [PMID: 41786383](https://pubmed.ncbi.nlm.nih.gov/41786383/). *J Allergy Clin Immunol Pract*. [Review / Meta-Analysis]
Pérez de Llano L (2026). [PMID: 41786384](https://pubmed.ncbi.nlm.nih.gov/41786384/). *J Allergy Clin Immunol Pract*. [Review / Meta-Analysis]
Kütting D (2026). [PMID: 41661280](https://pubmed.ncbi.nlm.nih.gov/41661280/). *Radiologie (Heidelb)*. [Review / Meta-Analysis]
Jha SK (2026). [PMID: 32491456](https://pubmed.ncbi.nlm.nih.gov/32491456/). *Unknown Journal*. [Review / Meta-Analysis]
Sumi T (2026). [PMID: 41710012](https://pubmed.ncbi.nlm.nih.gov/41710012/). *Respirol Case Rep*. [Clinical Trial Publication]
Hashimoto T (2025). [PMID: 39926405](https://pubmed.ncbi.nlm.nih.gov/39926405/). *Ann Thorac Med*. [Case Report / Case Series]
AI-curated news mentioning idiopathic chronic eosinophilic pneumonia
Updated Aug 10, 2026
A study reports three-year sustained remission with mepolizumab in patients with idiopathic chronic eosinophilic pneumonia. This finding highlights the potential of mepolizumab as a long-term treatment option for this rare eosinophilic disease.